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1  | INTRODUCTION
 Blocking the renin- angiotensin system (RAS) in the management of 
hypertension in African-American (AA) patients has had varying re-
sults for the treatment of hypertension. In fact, the modest effective-
ness of angiotensin receptor blocker (ARB) and angiotensin- converting 
enzyme inhibitor (ACEI) monotherapy trials have led to the avoidance 
of these classes of therapies as an initial option in the treatment of 
hypertension in AAs.1–3 In addition, there are proven racial variations 
in clinical phenotype and genetic characteristics, making stratification 
by race more than just a physiologic grouping in trials of cardiovascu-
lar medications. The AA population has a disproportionate burden of 
cardiovascular disease as well as a heterogeneous response to med-
ications (intraracial variability).4 Clinicians should not assume that all 
AAs are a homogenous entity with the same response to a particu-
lar class of antihypertensive medication, including ARBs. Potentially, 
ARBs could allow a significant number of AAs to reach their target 
blood pressure (BP) if effective and well- tolerated.
Azilsartan medoxomil (AZL- M) is a prodrug that is quickly hydro-
lyzed to the active moiety azilsartan (AZL), a potent and highly selec-
tive ARB with estimated bioavailability of 60% and elimination half- life 
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The efficacy and safety of azilsartan medoxomil (AZL- M) were evaluated in African-
American patients with hypertension in a 6- week, double- blind, randomized, placebo- 
controlled trial, for which the primary end point was change from baseline in 24- hour 
mean systolic blood pressure (BP). There were 413 patients, with a mean age of 
52 years, 57% women, and baseline 24- hour BP of 146/91 mm Hg. Treatment differ-
ences	in	24-	hour	systolic	BP	between	AZL-	M	40	mg	and	placebo	(−5.0	mm	Hg;	95%	
confidence	interval,	−8.0	to	−2.0)	and	AZL-	M	80	mg	and	placebo	(−7.8	mm	Hg;	95%	
confidence	interval,	−10.7	to	−4.9)	were	significant	(P≤.001	vs	placebo	for	both	com-
parisons). Changes in the clinic BPs were similar to the ambulatory BP results. Incidence 
rates of adverse events were comparable among the treatment groups, including those 
of a serious nature. In African-American patients with hypertension, AZL- M signifi-
cantly reduced ambulatory and clinic BPs in a dose- dependent manner and was well 
tolerated.
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of approximately 11 hours.5 Superior antihypertensive efficacy to 
valsartan and olmesartan has been demonstrated in three clinical 
trials6–8; this greater efficacy may be related to the more potent and 
persistent binding of AZL to the angiotensin II type 1 receptor relative 
to other ARBs.9,10 From prior pivotal studies evaluating the safety and 
efficacy of AZL- M vs placebo and other ARBs,6-8 a subgroup analysis 
in AA patients demonstrated significant reductions in 24- hour systolic 
BP (SBP) vs placebo.11 The present trial was a dedicated study in AAs 
with stages 1 and 2 hypertension designed to evaluate both the effi-
cacy and safety of AZL-M vs. placebo in this population. The primary 
end point was the change in 24- hour mean SBP, as determined by 
ambulatory BP monitoring (ABPM). Given the high prevalence of hy-
pertension and the lower efficacy rates of ARBs in AA patients, as well 
as the underrepresentation of AAs in hypertension clinical trials, this 
study addressed an important medical need.
2  | METHODS
2.1 | Patients and study design
This was a 6- week, randomized, double- blind, multicenter, placebo- 
controlled study comparing the antihypertensive effects and safety 
and tolerability of AZL- M, 40 or 80 mg once daily, with placebo in AA 
patients with stages 1 or 2 systolic hypertension. The protocol con-
formed	to	the	Declaration	of	Helsinki	and	regional	regulatory	guide-
lines, and the study was approved by regional institutional review 
boards (IRBs). Each patient signed an IRB- approved consent form 
before any study procedures were initiated. Eligible patients were 
randomized after participating in a 3- to 4- week washout of previous 
antihypertensive therapy that coincided with a 2- week single- blind, 
placebo run- in period.
At randomization, each patient was required to be 18 years or older, 
with	a	clinic	SBP	≥150	and	≤180	mm	Hg	and	a	24-	hour	mean	SBP	≥130	
and	≤170	mm	Hg.	Exclusion	criteria	included	known	or	suspected	sec-
ondary hypertension or severe diastolic hypertension (seated diastolic 
[DBP]	 >114	mm	Hg);	 severe	 renal	 impairment	 (estimated	 glomerular	
filtration rate <30 mL/min/1.73 m2); history of a major cardiovascular 
event in the previous 6 months; type 1 or poorly controlled type 2 dia-
betes	mellitus	(glycated	hemoglobin	>8%);	poor	compliance	with	study	
medication during the placebo run- in period; or hyperkalemia (serum 
potassium	concentration>upper	limit	of	normal	for	the	reference	lab-
oratory). In addition, night- shift workers, pregnant or nursing women, 
and women of childbearing potential not using approved means of con-
traception were excluded from participation. Concomitant medications 
known to affect BP were not permitted; these medications were listed 
in the protocol and available to all study personnel.
Seated BP was measured in the clinic at baseline and at weeks 
2, 4, and 6, and ABPM was performed at baseline and week 6. Clinic 
BP was measured in triplicate in the nondominant arm using an auto-
mated	BP	monitor	(Omron	HEM	705-	CP,	Lake	Forest,	IL,	USA)	after	
the patient was seated for 5 minutes. Every effort was made to en-
sure that the clinic BP readings were obtained approximately 24 hours 
after the last dose of study medication (ie, at trough) and before other 
procedures, including venipuncture. ABPM was performed with the 
Spacelabs 90207 device (Spacelabs, Inc., Issaquah, WA, USA), and was 
initiated in the morning immediately after dosing. The ABPM device 
measured BP every 15 minutes between 6 am and 10 pm and every 
20 minutes between 10 pm and 6 am. To pass the minimum quality- 
control	criteria,	each	ABPM	recording	must	have:	(1)	been	≥24	hours	
in	duration;	 (2)	 captured	≥80%	of	 the	possible	 readings;	 (3)	had	≤2	
nonconsecutive hours with <1 valid reading; and (4) had no consec-
utive hours with <1 valid reading. If these criteria were not met, the 
patient was asked to repeat the procedure within 5 days. If the re-
peated ABPM procedure also failed, the ABPM data were considered 
nonevaluable.
2.2 | Statistical analyses
The primary end point was change from baseline to week 6 in 24- hour 
mean SBP by ABPM, and the key secondary end point was change 
in trough sitting clinic SBP (referred to as clinic SBP). Changes in 24- 
hour	mean	DBP	by	ABPM	and	clinic	DBP	were	also	evaluated,	as	were	
the proportion of responders. The definition of response included 
achievement of: (1) clinic SBP <140 mm Hg and/or a reduction of 
≥20	mm	Hg	from	baseline;	(2)	clinic	DBP	<90	mm	Hg	and/or	a	reduc-
tion	of	≥10	mm	Hg	from	baseline;	or	both	1	and	2.	Subgroup	analyses	
of the primary and key secondary analyses were conducted by age, 
sex, body mass index, baseline 24- hour mean SBP, and estimated glo-
merular filtration rate.
The primary efficacy analysis was based on an analysis of cova-
riance model that included treatment as a fixed effect and baseline 
24- hour mean SBP by ABPM as a covariate, and utilized the last- 
observation- carried- forward principle. The intention- to- treat approach 
was used for the primary efficacy analysis for all randomized patients 
with at least one dose of study medication. A patient was included in 
the primary analysis only when there was both a baseline value and at 
least one postbaseline value. Similar statistical methods were used to 
analyze the other secondary efficacy end points that were continuous 
variables.
All statistical tests were two- sided and results were presented as 
treatment differences with 95% confidence intervals (CIs) and P val-
ues at the 5% significance level. Type 1 error was controlled for the 
primary analysis by using the principle of “closed” testing.12 For the 
key secondary efficacy variable, the same statistical model and test-
ing procedure used for the primary end point were used. Given the 
assumptions of a standard deviation of 13 mm Hg and a 20% dropout 
rate, the sample size of this study provided at least 90% power to de-
tect a difference of 6 mm Hg between each of the AZL- M treatment 
groups and placebo for the primary end point.
Safety measures included adverse events, clinical laboratory re-
sults (including pregnancy testing), physical examination findings, and 
electrocardiographic data. All adverse events observed by the inves-
tigator or reported spontaneously by the patient were recorded and 
further characterized by the investigator as being nonserious or seri-
ous; whether the event led to discontinuation of treatment was also 
recorded. Safety laboratory parameters of interest that were measured 
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at each visit included renal and hepatic function tests and serum po-
tassium levels. Blood samples were analyzed by a central laboratory 
(ICON	Laboratories,	Farmingdale,	NY,	USA).
3  | RESULTS
A total of 1266 patients were screened, and 916 patients were en-
rolled in the single- blind placebo run- in period at 74 principal inves-
tigators	in	the	United	States	and	Puerto	Rico.	Of	these	patients,	413	
fully met the entry criteria and were randomly assigned to one of 
three treatment arms as follows: 138 patients to placebo, 138 pa-
tients to AZL- M 40 mg, and 137 patients to AZL- M 80 mg. A total of 
365 of the 413 randomized patients completed 6 weeks of treatment 
as planned: 123 (89%) in the placebo arm, 126 (90%) in the AZL- M 
40-	mg	arm,	and	116	(85%)	in	the	AZL-	M	80-	mg	arm.	Discontinuation	
rates were low; the most common reason for premature discontinua-
tion was voluntary withdrawal (n=14, 3.4%) (Figure 1). There were no 
major differences in baseline characteristics among the three treat-
ment groups (Table 1). The mean age was 52 years, and a greater 
percentage of the participants were women (57%). Mean baseline 
clinic BP was approximately 158/96 mm Hg and 24- hour mean BP 
was 146/91 mm Hg.
3.1 | Efficacy findings
The absolute changes from baseline on ambulatory BP after 6 weeks 
of therapy for all the treatments are shown in Figure 2. Significant 
dose- related reductions in 24- hour mean SBP were observed for 
AZL- M 40 and 80 mg. The treatment difference between AZL- M 
40	mg	 and	 placebo	 for	 24-	hour	 mean	 SBP	 (−5.0	mm	Hg;	 95%	 CI,	
−8.0	to	−2.0)	and	AZL-	M	80	mg	and	placebo	(−7.8	mm	Hg;	95%	CI,	
−10.7	to	−4.9)	were	both	statistically	significant	(P≤.001	vs	placebo	
for both comparisons). Changes in daytime and nighttime BP were 
similar and significantly greater with both doses of AZL- M vs pla-
cebo (Figure 2). Hourly SBPs with AZL- M 40 and 80 mg were both 
consistently lower than with placebo throughout the dosing interval 
(Figure 3).
The effect of each treatment on clinic BP at week 6, the key sec-
ondary end point, is shown in Figure 4. Placebo- subtracted decreases 
in	the	clinic	SBP	were	–6.5	mm	Hg	with	AZL-	M	40	mg	(95%	CI,	−10.2	
to	−2.8)	and	−6.5	mm	Hg	with	AZL-	M	80	mg	(95%	CI,	−10.3	to	−2.8),	
respectively, and were statistically significant (P≤.001	vs	placebo	for	
both comparisons). A larger proportion of patients receiving AZL- M 
achieved a reduction of clinic SBP of <140 mm Hg and/or a reduction 
of	≥20	mm	Hg	(≈40%)	compared	with	placebo	(25%).
Changes	in	DBP,	as	measured	by	both	ambulatory	and	clinic	mea-
surements, were statistically significantly greater with both doses of 
AZL- M vs placebo (Figures 2 and 4). Placebo- subtracted mean re-
ductions	 in	 24-	hour	DBP	were	 −3.4	mm	Hg	 (95%	CI,	 −5.5	 to	 −1.4)	
for	AZL-	M	40	mg	and	−5.8	mm	Hg	(95%	CI,	−7.8	to	−3.8)	for	AZL-	M	
80 mg (P≤.001 vs placebo for both comparisons). Placebo- subtracted 
mean	 reductions	 in	 clinic	 DBP	were	 −3.1	mm	Hg	 (95%	 CI,	 −5.2	 to	
−1.0)	for	AZL	40	mg	and	−3.0	mm	Hg	(95%	CI,	−5.1	to	−0.8)	for	AZL-	M	
80 mg (P=.004 and P=.006 vs placebo, respectively).
3.2 | Safety findings
Rates of treatment- emergent adverse events were comparable in 
the three treatment groups (Table 2). Treatment- emergent adverse 
events were generally mild to moderate in severity. The most common 
adverse events during the trial were headache, increased creatine 
phosphokinase, and urinary tract infection (Table 2). Four patients ex-
perienced serious adverse events, three in the AZL- M 40- mg group 
F IGURE  1 Patient	disposition.	Data	
are expressed as number (percentage). 
The most common reasons for permanent 
discontinuation from the study are 
listed. The category “other” includes 
discontinuations that were due to reasons 
other than an adverse event, lack of 
efficacy, voluntary withdrawal, lost to 
follow- up, protocol deviation, or pregnancy. 
Patients could have had more than one 
reason for discontinuation, but only the 
primary reason is presented here. AZL- M 
indicates azilsartan medoxomil
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Characteristic
Placebo 
n=138
AZL- M 40 mg 
n=138
AZL- M 80 mg 
n=137
Age, y 52±11 52±11 51±10
Male/female, % 44/57 44/57 42/58
Body mass index, kg/m2 32.9±7.4 31.4±6.3 31.6±7.7
Diabetes,	%b 13.8 12.3 9.4
Clinic BP, mm Hg 158/96±13/10 157/97±14/10 159/95±14/10
24- h mean BP, mm Hg 145/91±10/9 146/92±11/9 147/92±11/10
Daytime	BP,	mm	Hgc 148/94±11/10 149/95±11/10 150/95±11/11
Nighttime	BP,	mm	Hgd 137/82±13/11 138/83±14/11 139/84±13/12
aData	mean±standard	deviation	unless	specified	otherwise.
bSubjects	(Ns)	for	this	characteristic	are	from	the	safety	analysis	set	which	had	138,	137,	137	subjects	
for placebo, azilsartan medoxomil (AZL-M) 40 mg, and AZL-M 80 mg groups, respectively.
cDaytime	interval	is	from	6	am to 10 pm.
dNighttime	interval	is	from	12	am to 6 am.
Abbreviation: BP, blood pressure.
TABLE  1 Baseline Characteristics of 
Randomized Patientsa
F IGURE  2 Change from baseline 
(mm Hg) in ambulatory systolic blood 
pressure (SBP) and diastolic blood pressure 
(DBP)	at	week	6.	Data	are	least	squares	
mean (±standard error). Sample sizes are 
94, 94, and 101 for the placebo, azilsartan 
medoxomil (AZL- M) 40- mg, and AZL- M 80- 
mg groups, respectively, for each measure. 
*P≤0.001	vs	placebo.	†P<.05 vs placebo. BP 
indicates blood pressure
F IGURE  3 Hourly profiles of the 24- 
hour systolic blood pressure (BP) at week 
6.	Double-	blind	medication	dosing	was	
administered at hour 0. AZL- M indicates 
azilsartan medoxomil
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(diabetic ketoacidosis, cerebral hemorrhage, and an exacerbation of 
asthma) and one in the AZL- M 80- mg treatment group (vomiting). 
There were no deaths in the trial.
There were no differences in mean changes in serum creatinine, 
potassium, or liver enzymes observed among the three treatment 
groups.	No	participant	experienced	serum	potassium	>6	mmol/L.	One	
participant (0.7%) in the placebo treatment group and one participant 
in the 80- mg treatment group had an increase in serum creatinine 
≥50%	above	baseline	and	above	the	upper	limit	of	normal.	There	were	
no instances of a persistent increase in serum creatinine following dis-
continuation of study drug.
4  | DISCUSSION
The results of this trial demonstrate that AZL- M produced significant 
BP- lowering effects throughout the dosing interval in AA patients 
with hypertension and was well tolerated. The reductions in ambu-
latory and clinic BPs from baseline were highly significant and clini-
cally important, showing greater dose- related reductions for 80 mg vs 
40 mg in this patient population.
There has been a longstanding impression that RAS inhibitors are 
much less efficacious in AA patients with hypertension when com-
pared with their white counterparts (which is clearly the case for a 
number of agents, including telmisartan, another fairly long- acting 
ARB). These impressions were based on the theory that the RAS is less 
active in AAs vs whites because of the tendency towards suppressed 
circulating renin activity in AAs13,14 and the lesser average BP re-
sponse in AA as compared with white hypertensive patients to ACEIs 
when used as monotherapy.1,15-18 However, circulating renin levels are 
not fully suppressed in the majority of AAs.19 Also, suppressed renin 
production and circulating renin levels from high sodium intake have 
been associated with higher levels of vascular angiotensin II produc-
tion20 and a greater activation of RAS in healthy AAs as compared with 
whites.21 The excessive rates of target organ injury such as chronic 
kidney disease and proteinuria in hypertensive AAs have all been 
associated with RAS activation,22 which supports the evidence from 
prior studies demonstrating that ACEIs and ARBs are effective antihy-
pertensives for slowing the progression of kidney disease in patients 
with diabetic and nondiabetic chronic kidney disease.23-27 The basis 
for the primary use of ACEIs in the AA population with hypertension 
F IGURE  4 Change from baseline 
(mm Hg) in clinic systolic blood pressure 
(SBP)	and	diastolic	blood	pressure	(DBP)	
at	week	6.	Data	are	least	squares	mean	
(±standard error). Sample sizes are 133, 
134, and 130 for the placebo, azilsartan 
medoxomil (AZL- M) 40- mg, and AZL- M 80- 
mg groups, respectively, for each measure. 
*P<.01 vs placebo. BP indicates blood 
pressure
AEs, No. (%)
Placebo 
n=138
AZL- M 40 mg 
n=137
AZL- M 80 mg 
n=137
Any AEs 49 (35.5) 50 (36.5) 45 (32.8)
AEs leading to discontinuation 1 (0.7) 3 (2.2) 2 (1.5)
Serious AEs 0 3 (2.2) 1 (0.7)
Deaths 0 0 0
Most frequently reported AEs
Headache 3 (2.2) 6 (4.4) 9 (6.6)
Blood CK increased 6 (4.3) 4 (2.9) 3 (2.2)
Urinary tract infection 6 (4.3) 3 (2.2) 3 (2.2)
AEs of special interest
Dizziness 1 (0.7) 4 (2.9) 3 (2.2)
Hyperkalemiaa 0 0 1 (0.7)
Abbreviations: AEs, adverse events; AZL- M, azilsartan medoxomil; CK, creatine kinase.
a≥5.5	mmol/L.
TABLE  2 Safety	Findings	During	the	
Trial
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is	well	documented	in	the	African	American	Study	of	Kidney	Disease	
and Hypertension (AASK), which demonstrated superiority of ACEI 
over β- blocker and dihydropyridine calcium channel blocker therapy 
for slowing the rate of decline in the glomerular filtration rate in AA 
patients with moderate renal insufficiency and proteinuria.28
Trials comparing the efficacy of various ARBs in reducing CV out-
comes of interest have consistently shown a disproportionately lower 
representation of AAs in those studies compared with their white coun-
terparts.1,22 Therefore, evidence- based recommendations regarding 
superiority or inferiority of ARBs vs ACEIs in managing hypertension 
or its related comorbidities are difficult to determine. Few studies have 
evaluated the efficacy of ARBs as monotherapy for the treatment of 
hypertension	specifically	in	the	AA	population.	One	such	study	was	the	
Association of Black Cardiologists (ABC) trial,29 in which the efficacy of 
the RAS blocker candesartan was explored in AA patients with hyper-
tension. In this study, small but significant reductions in clinic BP were 
observed	vs	placebo	(−5/−2.5	mm	Hg)	after	8	weeks	of	treatment	with	
candesartan. In fact, most of the evidence for efficacy and tolerability of 
RAS inhibition in AA patients has been derived from subgroup analyses.
At least two studies have compared the efficacy of different ARBs 
in black vs nonblack patients, in post hoc subgroup analyses. In one 
study, Giles and colleagues30 compared the efficacy of olmesartan 
medoxomil, losartan potassium, and valsartan in black vs nonblack 
patients with hypertension, in a 12- week, placebo- controlled forced- 
titration (at 4 and 8 weeks) study. Significant reductions in SBP were 
observed by 2 weeks of treatment with all three ARBs in the nonblack 
patients versus placebo; however, significant reductions vs placebo 
were not observed in the black patients until 8 weeks of treatment 
(and titration to double the starting dose), and only with olmesartan 
treatment. These results show that clinically relevant BP reductions 
can be achieved with RAS blockade in black patients, but may require 
higher doses than their nonblack counterparts or more potent RAS 
agents and likely combination therapy.
White and coworkers6–8,11 previously described the comparative 
BP- lowering efficacy and tolerability of AZL- M vs olmesartan and val-
sartan in black patient subgroups from three large, randomized trials 
of patients with stage 1 and 2 hypertension. AZL- M’s efficacy was 
greater than olmesartan and valsartan at their highest clinically used 
doses after 6 to 8 weeks of treatment and was well tolerated in black 
patients with hypertension.11 However, even though there were rea-
sonable proportions of black patients in the individual pivotal trials 
comparing AZL-M to placebo,6-8 the subgroup analyses were explor-
atory and the total number of patients on either dose of AZL-M was 
relatively low.11 The results of this larger, dedicated study are consis-
tent with the previous subgroup analyses and definitively demonstrate 
clinically meaningful reductions in clinic and 24-hour mean SBP of 
AZL-M in the AA population.6–8,11
5  | CONCLUSIONS
The results from our study demonstrate that an ARB with potent 
efficacy such as AZL- M was able to provide clinically meaningful 
reductions in ambulatory and clinic BP when used as monother-
apy in AA patients. It is also noteworthy that use of AZL- M shows 
greater efficacy in AA patients when combined with other types 
of antihypertensives, particularly the long- acting diuretic chlortha-
lidone and the long- acting dihydropyridine calcium channel blocker 
amlodipine.31–33 Race and/or ethnicity should not be a deterrent to 
clinicians for using ARBs as evidenced by our data. AZL- M can be 
considered as a potentially effective and well- tolerated monother-
apy or in combination with other therapy for this often difficult to 
manage population.
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the policy of including underserved populations in large clinical trials 
conducted	in	the	United	States	and	abroad.	In	April	2015,	Dr	Saunders	
passed away, leaving many family members, friends, and a host of 
medical professionals with a great sense of loss; however, his legacy 
as a father, husband, clinician, and researcher will inspire us all to strive 
to uphold and honor his dedication to science, medicine, and preserv-
ing human life. The authors would also like to acknowledge Ebenezer 
O.	Oloyede,	MD,	and	Jude	Ediae,	MD,	for	their	contributions	to	this	
manuscript.
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